Abstract
Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality. More effective treatment approaches are needed. Traditionally, whole-brain radiotherapy has been used for palliation. With advances in radiation oncology, stereotactic radiosurgery and hypofractionated stereotactic radiotherapy have been utilized for RCC brain metastases, producing excellent outcomes. This review details the role of radiotherapy in various subgroups of patients with RCC brain metastases as well as the associated toxicities and outcomes. Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 603-613 |
| Number of pages | 11 |
| Journal | ONCOLOGY |
| Volume | 20 |
| Issue number | 6 |
| State | Published - 2006 |
ASJC Scopus subject areas
- Oncology
- Cancer Research